US4983400A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release combination of carbidopa/levodopa
Assignee: Merck and Co Inc
•
Filing: 1989-12-01
•
Granted: 1991-01-08
•
Expires: 2009-12-01
Abstract
Abstract A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.
Inventors
- 👤 Robert E. Dempski
- 👤 Edward C. Scholtz
- 👤 Donald W. Nibbelink
- 👤 Scott A. Reines
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 21:34
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
49 words
A controlled release solid oral dosage formulation consisting essentially of a uniform dispersion of 5-300 mg of carbidopa, 20-1200 mg of levodopa in a polymer vehicle of 2 to 120 mg of polymethyl methacrylate, whereby following administration the carbidopa and levodopa are released slowly and simultaneously from the formulation.
Claim 2
Dependent Claim
49 words
A controlled release solid oral dosage formulation consisting essentially of a uniform dispersion of 5-300 mg of carbidopa, 20-1200 mg of levodopa in a polymer vehicle of 2 to 120 mg of polymethyl methacrylate, whereby following administration the carbidopa and levodopa are released slowly and simultaneously from the formulation.
Claim 3
Dependent Claim
52 words
The controlled release solid oral dosage formulation of claim 1 consisting essentially of a uniform dispersion of 25-100 mg of carbipopa, 100-400 mg of levodopa, in a polymer vehicle of 2 to 120 mg of polymethyl methacrylate, whereby following administration the carbidopa and levodopa are released slowly and simultaneously from the formulation.
Claim 4
Dependent Claim
20 words
The formulation of claim 1 comprising 400 mg of levodopa, 100 mg of carbidopa and 120 mg of polymethyl methacrylate.
References Cited (Backward Citations)
USRE29892E
Cited
US3995058A
Cited
US4014987A
Cited
US4177056A
Cited
US3961041A
Cited
US4021555A
Cited
US4389415A
Cited
US4304591A
Cited
US4190672A
Cited
US4469693A
Cited
US4469695A
Cited
US4469694A
Cited
EP0036145A1
Cited
US4423099A
Cited
US4389330A
Cited
US4329356A
Cited
US4327725A
Cited
US4421767A
Cited
US4413012A
Cited
US4424235A
Cited
DE3232873A1
Cited
US4497826A
Cited
US4606909A
Cited
US4446138A
Cited
US4389393A
Cited
US4389393B1
Cited
US4440740A
Cited
US4783337A
Cited
US4548990A
Cited
US4529603A
Cited
EP0147780A2
Cited
US4692336A
Cited
US4844984A
Cited
US4624848A
Cited
US4749576A
Cited
US4851228A
Cited
US4685918A
Cited
US4840799A
Cited
EP0237506A1
Cited
EP0252290A2
Cited
US4826875A
Cited
US4900755A
Cited
EP0253490A1
Cited
EP0260236A1
Cited
US4938967A
Cited
EP0290891A1
Cited
US4883666A
Cited
US4940465A
Cited
US4876093A
Cited
US4855144A
Cited
US4806360A
Cited
EP0320051A1
Cited
US4832957A
Cited
EP0324947A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-07 | 1994-07-09 | 1995-01-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-07 | 1998-07-09 | 1999-01-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-07 | 2002-07-09 | 2003-01-08 | $7700.00 | Window Closed / Lapsed |